Sens. Back Long-Term Protections For Biologic Drugs

Law360, New York (October 26, 2009, 8:25 PM EDT) -- In the tug-of-war over how to regulate generic versions of biologic treatments, a group of senators has joined the faction pulling for a full 12-year term of data exclusivity, saying the measure is necessary to reward pioneering companies and incentivize further innovation in the field.

In a letter Friday, a dozen senators signed a letter urging Majority Leader Sen. Harry Reid, D-Nev., to support the 12-year exclusivity period as lawmakers prepare legislation aimed at creating a regulatory pathway for brand-name biologics, also known as biosimilars....
To view the full article, register now.